Myeloma Patients Europe urges CHMP committee to approve plitidepsin for relapsed myeloma
Myeloma Patients Europe (MPE) has written to the Chair of the Committee for Human Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) to provide the patient viewpoint on the importance of plitidepsin (Aplidin®) for relapsed and refractory myeloma patients across Europe. We have outlined how important it is for patients across Europe to gain access to effective drugs that have new mechanisms of action.